Imperial College London
Alternate

Professor Robin Carhart-Harris

Faculty of Medicine, Department of Brain Sciences

Visiting Professor
 
 
 
//

Contact

 

+44 (0)20 7594 7992r.carhart-harris

 
 
//

Assistant

 

Miss Bruna Cunha +44 (0)20 7594 7992

 
//

Location

 

Burlington DanesHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Nayak:2022:osf.io/sb5ur,
author = {Nayak, SM and Bari, BA and Yaden, DB and Spriggs, MJ and Rosas, F and Peill, JM and Giribaldi, B and Erritzoe, D and Nutt, D and Carhart-Harris, R},
doi = {osf.io/sb5ur},
title = {A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression},
url = {http://dx.doi.org/10.31234/osf.io/sb5ur},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - <p>Objectives: To perform a Bayesian reanalysis of a recent trial of psilocybin (COMP360) versus escitalopram for Major Depressive Disorder (MDD) in order to provide a more informative interpretation of the indeterminate outcome of a previous frequentist analysis.Design: Reanalysis of a two-arm double-blind placebo controlled trial.Participants: Fifty-nine patients with MDD.Interventions: Two doses of psilocybin 25mg and daily oral placebo versus daily escitalopram and 2 doses of psilocybin 1mg, with psychological support for both groups.Outcome measures: Quick Inventory of Depressive Symptomatology–Self-Report (QIDS SR-16), and three other depression scales as secondary outcomes: HAMD-17, MADRS, and BDI-1A.Results: Using Bayes factors and ‘skeptical priors’ which bias estimates towards zero, for the hypothesis that psilocybin is superior by any margin, we found indeterminate evidence for QIDS SR-16, strong evidence for BDI-1A and MADRS, and extremely strong evidence for HAMD-17. For the stronger hypothesis that psilocybin is superior by a ‘clinically meaningful amount’ (using literature defined values of the minimally clinically important difference), we found moderate evidence against it for QIDS SR-16, indeterminate evidence for BDI-1A and MADRS, and moderate evidence supporting it for HAMD-17. Furthermore, across the board we found extremely strong evidence for psilocybin’s non-inferiority versus escitalopram. These findings were robust to prior sensitivity analysis.Conclusions: This Bayesian reanalysis supports the following inferences: 1) that psilocybin did indeed outperform escitalopram in this trial, but not to an extent that was clinically meaningful—-and 2) that psilocybin is almost certainly non-inferior to escitalopram. The present results provide a more precise and nuanced interpretation to previously reported results from this trial, and support the need for further research into the relative efficacy of
AU  - Nayak,SM
AU  - Bari,BA
AU  - Yaden,DB
AU  - Spriggs,MJ
AU  - Rosas,F
AU  - Peill,JM
AU  - Giribaldi,B
AU  - Erritzoe,D
AU  - Nutt,D
AU  - Carhart-Harris,R
DO  - osf.io/sb5ur
PY  - 2022///
TI  - A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression
UR  - http://dx.doi.org/10.31234/osf.io/sb5ur
ER  -
Download